ArticleEquine veterinary journal2026
Chronic hepatitis in horses with persistent equine hepacivirus infection.
Article in Equine veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of mosquito transmission of equine hepacivirus in laboratory and field studies.Journal of medical entomology · 2026Article
- Chronic hepatitis in horses with persistent equine hepacivirus infection.Equine veterinary journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundEquine hepacivirus (EqHV) is closely related to hepatitis C virus (HCV), which causes persistent infection and chronic hepatitis in people. Information on persistent EqHV infection and hepatitis is limited.
objectivesTo report 19 cases of chronic hepatitis and persistent EqHV infection. STUDY
designMixed retrospective and prospective case series.
methodsInclusion criteria were: (1) chronic hepatitis, defined as persistently increased serum liver biomarkers, increased serum liver biomarkers accompanied by histopathological evidence of chronicity, for example, fibrosis, or both; (2) positive serum or liver EqHV RT-qPCR; and (3) available liver histopathology. Horses were excluded if they became serum EqHV RT-qPCR undetectable, died, or were euthanised within 6 months of EqHV detection. Liver biopsies were independently reviewed.
resultsTwenty-nine horses met inclusion criteria. Ten were subsequently excluded (two cleared EqHV, 8 died within 6 months). For the remaining 19 horses, the median duration of documented hepatitis was 18.4 (range, 5.2-120) months and documented EqHV viremia was 14.8 (range, 6.9-55.6) months. Histopathological findings mirrored those seen in humans with chronic HCV including fibrosis, lymphocytic infiltrate, lymphoid aggregates, and individual hepatocyte necrosis. One horse was diagnosed with bacterial cholangiohepatitis, and the remainder had no definitive etiologic diagnosis. Bacterial infection, equine parvovirus-hepatitis infection, and equine multinodular pulmonary fibrosis were frequent comorbidities. MAIN LIMITATIONS: A direct causal link between EqHV viremia and hepatitis cannot be made from these data.
conclusionsSome horses with persistent EqHV infection develop chronic hepatitis and liver failure, with clinical and histopathological findings resembling HCV in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.